PDF 
Views 
Share
Glutathione-s-transferase and CYP1A1FNx012A polymorphisms in acute lymphoblastic leukemia patients
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2012; 33(02): 137
DOI: DOI: 10.4103/0971-5851.99756
Publication History
Article published online:
13 April 2022
© 2012. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Sir,
A recent publication on glutathione-s-transferase and cytochrome P-450 1A1*2A polymorphisms in acute lymphoblastic leukemia patients is interesting.[1] Suneetha et al. concluded that glutathione-s-transferase 1 (Ile/Val) polymorphism has a role in the susceptibility to acute lymphoblastic leukemia, and also influences the treatment outcome.[1] The main problem of this report is that the investigations are on few polymorphisms without assessment of other confounding interference factors. It should be noted that having the studied polymorphism might not mean that there is or there is no other polymorphism contributing to the final outcome. In addition, other epigenetic factors can also determine the outcome of treatment.[2]